ADC Therapeutics director granted 45K RSUs

ADC Therapeutics SA director Robert Azelby reported routine equity compensation and related tax withholding.

Rhea-AI Filing Summary

ADC Therapeutics SA director Robert Azelby reported routine equity compensation and related tax withholding. On June 1, 2026, he received a grant of 45,000 Common Share RSUs under the 2019 Equity Incentive Plan for his service as a director, vesting at the earlier of one year from grant or the 2027 annual meeting. On June 3, 2026, 12,600 Common Shares were withheld by the company at $3.08 per share to satisfy tax obligations from previously vested RSUs. After these transactions, Azelby directly holds 112,805 Common Shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Azelby Robert

Role Director

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Shares	12,600	$3.08	$39K
Grant/Award	Common Shares	45,000	$0.00	$0.00

Holdings After Transaction: Common Shares — 112,805 shares (Direct)

Footnotes (2)

1. F1. Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Key Figures

RSU grant size: 45,000 shares Tax-withheld shares: 12,600 shares Tax-withholding price: $3.08 per share +1 more

4 metrics

RSU grant size 45,000 shares Annual director RSU grant on June 1, 2026

Tax-withheld shares 12,600 shares Shares withheld for tax obligations on June 3, 2026

Tax-withholding price $3.08 per share Price used for 12,600 withheld common shares

Post-transaction holdings 112,805 shares Common shares directly held after reported transactions

Key Terms

restricted stock units ("RSUs"), 2019 Equity Incentive Plan, tax withholding obligations

3 terms

restricted stock units ("RSUs") financial

"Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2019 Equity Incentive Plan financial

"annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director"

tax withholding obligations financial

"withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ADC Therapeutics (ADCT) director Robert Azelby report?

Robert Azelby reported two equity-related transactions: a grant of 45,000 restricted stock units and the withholding of 12,600 common shares for taxes. Both transactions are compensation-related and not open-market share purchases or sales.

How many ADC Therapeutics (ADCT) shares did Robert Azelby receive in his latest RSU grant?

He received 45,000 restricted stock units tied to ADC Therapeutics common shares. The RSUs were granted under the company’s 2019 Equity Incentive Plan as annual director compensation and will vest based on continued board service and a specified future date.

Why were 12,600 ADC Therapeutics (ADCT) shares withheld from Robert Azelby?

The 12,600 common shares were withheld by ADC Therapeutics to cover Robert Azelby’s tax withholding obligations from the vesting of previously granted restricted share units. This tax-withholding disposition is a non-market event rather than an open-market share sale.

What is Robert Azelby’s ADC Therapeutics (ADCT) shareholding after these Form 4 transactions?

Following the RSU grant and subsequent tax share withholding, Robert Azelby directly holds 112,805 ADC Therapeutics common shares. This figure reflects his updated direct ownership position as reported in the latest Form 4 filing with the SEC.

How do the new RSUs for ADC Therapeutics (ADCT) director Robert Azelby vest?

The 45,000 RSUs vest on the earlier of one year from the June 1, 2026 grant date or the date of the 2027 annual meeting of shareholders, subject to Robert Azelby’s continued service as a director on ADC Therapeutics’ board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Azelby Robert

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NEW JERSEY 07974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/01/2026		A		45,000(1)	A	$0	125,405	D
Common Shares	06/03/2026		F(2)		12,600	D	$3.08	112,805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa Kallebo, as Attorney-in-Fact for Robert Azelby	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)